Soligenix (NASDAQ: SNGX - Get Free Report) and Zura Bio (NASDAQ: ZURA - Get Free Report) are both sm

Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.12) per share which beat the analyst consen

PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Compa

Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Frida

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.co

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company fo

Thermostability, immunogenicity and efficacy data against related viruses provides firm starting poi

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Tetra Technologies Inc. (NYSE: TTI) shares fell 15.06% in pre-market trading after announcing a $100

U.S. stocks traded mixed, Nasdaq down 0.3%. Dow up 0.59%, S&P 500 down 0.09%. Consumer discretio

US stocks mixed, Dow up 300 pts. Dow up 0.64%, NASDAQ down 0.34%. Consumer discretionary up 1.7%, en

Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares ro

Soligenix shares surged 72.32% in after-hours trading following rapid Bundibugyo virus vaccine devel

Thermostability, immunogenicity and efficacy data against related virusesmay provide rapid starting

https://www.cdc.gov/ebola/situation-summary/index.html

Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.28) per share which met the analyst consens

PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Compan

US stocks down, NASDAQ falls over 1% on Tuesday. Dow up 0.20%, NASDAQ down 1.24%, S&P 500 down 0

Soligenix ends Phase 3 FLASH2 study for HyBryte. CEO cites unanticipated results. See how this impac

US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy

Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company foc

PRINCETON, N.J., April 28, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Com

HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor® during 12-week t

HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor ® during 12-week

Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.29) per share which beat the analyst consen

Upcoming high-impact milestones include interim analysis in Q2 2026 and top-line results in H2 2026

Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company foc

PRINCETON, N.J., March 26, 2026 /PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Comp

Highlighting Positive Results in Comparison to Valchlor ® and in Real-World Use PRINCETON, N.J., Mar

AUSTIN, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organ

Expert Opinion on Investigational Drugs is an international monthly peer-reviewed journal, evaluatin

PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Com

https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03122026_SNGX_Bautz.pdf

Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company foc

PRINCETON, N.J., March 10, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Com

PRINCETON, N.J., Feb. 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Comp

PRINCETON, N.J., Feb. 24, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Comp

PRINCETON, N.J., Feb. 12, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Comp

Soligenix Inc. (NASDAQ: SNGX - Get Free Report) was the target of a significant drop in short intere

 Item 8.01.Other Events. On January 23, 2026, Soligenix, Inc. (the "Company") and Rodman &am

Study results support advancing SGX945 in this difficult-to-treat orphan diseaseResults suggest pote

Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest pot